Safety Study of LY3041658 in Healthy Participants

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3041658 in Healthy Subjects

The main purpose of this study is to evaluate the safety of LY3041658 in healthy participants, including first generation Japanese. The study will also investigate how the drug is processed and affects key immune cells. Study participation will last 4 months.

Protocol amended in January, 2016 to include first generation Japanese participants.

Inclusion Criteria:

• All:

  • Body mass index (BMI) between 18.0 to 32.0 kilogram per square meter (kg/m²).
  • Absolute neutrophil count at screening should be ≥1.8 and ≤7.2 x 10^3/microliter (uL), inclusive.

• First-generation Japanese:

  • Participant, biological parents, and biological grandparents must be of exclusive Japanese descent and born in Japan.
  • Are 20 to 65 years of age, inclusive, at the time of initial screening.

Exclusion Criteria:

- Have received antibody-based biologic agents (marketed or investigational) within 3 months or 5 half lives (t1/2) of the drug (whichever is longer) prior to screening.